TauRx Expands Alzheimer’s Programs

TauRx Therapeutics has expanded its international clinical program by adding 35 new research centers across the U.S. The addition of these clinical research centers means that more patients suffering from mild or moderate Alzheimer’s, and their caregivers, will have an opportunity to see if they qualify for participation in TauRx’s Alzheimer’s clinical trials, according to the company.

The company’s lead treatment, second generation tau aggregation inhibitor LMTX, is being evaluated in Phase III clinical trials for Alzheimer’s. LMTX targets the tangles of tau protein that develop in the brain.

TauRx’s Phase III studies are designed to evaluate the effects of LMTX on slowing and/or halting the progression of Alzheimer’s disease. The expansion of study centers in the U.S. includes areas such as Bennington, VT; Farmington Hills, MI; Waukesha, WI; and Creve Coeur, MO.